Cognition Therapeutics Q1 2025 Financial Update
Ticker: CGTX · Form: 10-Q · Filed: May 7, 2025 · CIK: 1455365
| Field | Detail |
|---|---|
| Company | Cognition Therapeutics INC (CGTX) |
| Form Type | 10-Q |
| Filed Date | May 7, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: financials, biotech, equity
TL;DR
Cognition Therapeutics' Q1 2025 capital down slightly to $59.8M from $61.9M YoY.
AI Summary
Cognition Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported $59,854,877 in Additional Paid-In Capital for the first quarter of 2025, compared to $61,974,755 for the same period in 2024. This filing details financial activities including common stock and retained earnings.
Why It Matters
This filing provides insight into Cognition Therapeutics' financial health and capital structure, which can influence investor confidence and future strategic decisions.
Risk Assessment
Risk Level: medium — The company operates in the biotechnology sector, which is inherently high-risk due to research and development costs and regulatory hurdles.
Key Numbers
- $59.86M — Additional Paid-In Capital (As of March 31, 2025)
- $61.97M — Additional Paid-In Capital (As of March 31, 2024)
Key Players & Entities
- Cognition Therapeutics, Inc. (company) — Filer of the 10-Q
- March 31, 2025 (date) — End of reporting period
- $59,854,877 (dollar_amount) — Additional Paid-In Capital for Q1 2025
- $61,974,755 (dollar_amount) — Additional Paid-In Capital for Q1 2024
FAQ
What were the primary drivers for the decrease in Additional Paid-In Capital from Q1 2024 to Q1 2025?
The filing does not explicitly detail the drivers for the decrease in Additional Paid-In Capital, but mentions 'AtMarketOfferingMember' and 'FollowOnPublicOfferingMember' activities for both periods.
What is the total amount of Common Stock reported as of March 31, 2025?
The filing indicates Common Stock transactions related to 'AtMarketOfferingMember' and 'FollowOnPublicOfferingMember' for the periods ending March 31, 2025, and March 31, 2024, but does not provide a specific total dollar amount for Common Stock as of March 31, 2025.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
What is the SIC code for Cognition Therapeutics Inc.?
The Standard Industrial Classification (SIC) code is 2836, for Biological Products (No Diagnostic Substances).
What is the business address of Cognition Therapeutics Inc.?
The business address is 2403 Sidney Street, Suite 261, Pittsburgh, PA 15203.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 7, 2025 regarding COGNITION THERAPEUTICS INC (CGTX).